Call For More Transparency In Clinical Trials
Pharmaceuticals are in decline as an industry due to over-regulation, lawsuits and cultural distrust. A new initiative from the European Medicines Agency, to commit to releasing all of the information from clinical trials once the marketing authorization process has ended, is being cheered by proponents of access to data but the pharmaceutical industry is less pleased.
Writing in an editorial, PLoS Medicine writes, "As 2013 begins, it is clear that critical times lie ahead for the publishing of clinical trials, which may define the relationship between pharmaceutical companies and the…